Anaesthesia complication rates

Article

Anaesthesia administered by sharp needles carries a greater risk of serious complications than subtenons cannula administration, according to a study published online ahead of print in Eye.

Anaesthesia administered by sharp needles carries a greater risk of serious complications than subtenons cannula administration, according to a study published online ahead of print in Eye.

Rob L. Johnston of Gloucestershire Eye Department, Cheltenham General Hospital, UK and colleagues evaluated the Cataract National Dataset, which contains electronically recorded patient data gathered from 12 UK National Health Service Trusts.

An ophthalmologist administered anaesthetic in 56.7% of the 55 567 operations performed; anaesthetic was administered by an anaesthetist for 42.1% of operations, and by an assistant in 0.3% of the cases (personnel administering anaesthesia in the remaining 0.9% was unrecorded).

Across all Trusts, local anaesthesia was used in 95.5% of cases; topical anaesthesia, 22.3%; topical and intracameral, 4.7%; subtenons, 46.9%; peribulbar, 19.5%; retrobulbar, 0.5%. Minor complications (≥1) associated with sharp needle or subtenons cannula administration occurred in 4.3% of cases, with subtenons administration being 2.3 times more likely than sharp needles to cause minor complications. Serious complications associated with sharp needle or subtenons cannula administration occurred in 0.066% of cases (n=25), with sharp needle administration being 2.5 times more likely than subtenons to cause serious complications.

The team noted that, although subtenons administration of anaesthesia was associated with a greater risk of minor complications, sharp needles were more likely to produce serious complications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.